Moderna Stock News

Pfizer Jab & GSK''s Antibody Drug Are Effective Against Omicron After teasing various aspects of his plan to protect Americans from the omciron variant (which is arriving at the start of the latest ''winter wave'') while the CDC quietly collects names of travelers who recently visited southern Africa, President Joe Biden is preparing to share his plan, which will impose tighter restrictions on foreign travelers while extending a mask mandate and (potentially) double down on vaccine restrictions for American workers (even as multiple federal judges have rejected the mandate). Biden''s comments are expected later on Thursday, but during the early hours of the US session, Germany''s outgoing Chancellor Angela Merkel and her successor, Olaf Scholz, agreed on a plan to effectively mandate vaccinations by imposing stringent restrictions on Germans who haven''t voluntarily gotten the jab. As governments scramble to use omicron as an excuse to crack down on the unvaccinated, makers of vaccines and COVID remedies have continued to share data about their products'' efficacy at combating the omicron variant.

While both vaccines were highly effective in preventing infection, hospitalization and death, the Moderna vaccine conferred a 21% lower risk of infection and a 41% lower risk of hospitalization.

The Omicron coronavirus variant has shaken up markets and caused global alarm over concerns about whether it could evade protection provided by widely used vaccines and prolong the public health crisis. Other vaccine makers including Moderna and Pfizer have also begun working on Omicron-tailored COVID-19 shots. Novavax''s COVID-19 vaccine received its first emergency use approval in Indonesia in early November followed by the Philippines.

In last trading session, Moderna Inc. (NASDAQ:MRNA) saw 21.35 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $310.61 trading at -$41.82 or -11.87% at ring of the bell on the day assigns it a market valuation of $120.03B. That closing price of MRNAs stock is at Moderna Inc. (NASDAQ:MRNA) Drops -11.87 Percent, But More Could Be Coming. Read More »

Hedge Funds Are Liquidating At A Furious Pace. And Retail Investors Are Buying It All Over the weekend , and then again on Monday we reported that It had been a catastrophic week for hedge funds: heading into Black Red Friday, losses were staggering with Goldman Prime reporting that many hedge funds were caught off-guard by news of the Omicron variant as they had bought Reopen stocks and sold Stay-at Home names in the past week. As a result, in the week ending Nov 25, GS Equity Fundamental L/S Performance Estimate fell -1.57% between 11/19 and 11/25, driven by alpha of -1.12% which was " the worst alpha drawdown in nearly six months " and beta of -0.45% (from market exposure and market sensitivity combined). It only got worse on Friday and then again Monday, when Moderna - the 3rd most popular short in the hedge fund universe with some $4.5BN of the stock held short by the 2 and 20 crowd... ... exploded higher, resulting in massive double-digits losses for funds who were aggressively short the name... and just in general as the following P&L charts from Goldman Prime show.

Futures Rebound Fizzles On Slowing iPhone Demand, Omicron Fears U.S. index futures regained some ground alongside Asian markets while European stocks slumped to session lows in a delayed response to yesterday''s late Omicron-driven US selloff, as markets remained volatile following the biggest two-day plunge in more than a year, spurred by concern about the omicron coronavirus variant and Federal Reserve tightening. Investors await data for unemployment claims, as well as earnings from companies including Dollar General and Kroger. Tech is the weakest sector, dropping in sympathy after Apple warned its suppliers of slowing iPhone demand. Nasdaq futures pared earlier gains of up to 0.8% to trade down 0.1% while S&P futures are only 0.2% higher after rising as much as 0.9%. While the knee-jerk reaction of stock investors may continue to be to take profits before the end of the year, there is plenty of liquidity available to drive stock prices higher as dip-buyers enter the market , Ed Yardeni wrote in a note.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus U.K. Signs Deal to Buy Incremental COVID-19 Vaccines From Moderna And

Europes drug watchdog launched an accelerated review Thursday of a Covid-19 vaccine by Franco-Austrian biotech firm Valneva, for which the EU has already signed a deal for up to 60 million doses. The jab which uses inactivated viruses rather than the new mRNA technology of the Pfizer or Moderna shots showed in trials []

The British government has agreed on deals to buy 114 million more Pfizer Inc (NYSE: PFE ) / BioNTech SE (NASDAQ: BNTX ) and Moderna Inc (NASDAQ: MRNA ) COVID-19 vaccine shots. The new contracts with Pfizer/BioNTech and Moderna were accelerated in light of the emergence of the new Omicron variant. These future supply deals include access to modified vaccines, if needed, to combat Omicron and future Variants of Concern. The deal involves an additional 60 million Moderna shots and 54 million Pfizer/BioNTech doses for next year and 2023. "These new deals Full story available on Benzinga.com

It''s not all bad news.

Government signs contracts to buy a total of 114 million additional Pfizer/BioNTech and Moderna doses for 2022 and 2023. Deals include 60 million additional doses of the Moderna vaccine and 54 million more Pfizer/BioNTech doses. New agreements to future proof booster programme sped up in light of new variant

Arbutus stock surges thanks to an appeals win against Moderna